Advertisement

Neurologische Komplikationen entzündlicher Darmerkrankungen

  • Oliver Bachmann
  • Natascha Wehnert
Chapter

Zusammenfassung

Mit einigen entzündlichen Darmerkrankungen sind neurologische Symptome assoziiert, die zum Teil das Krankheitsbild wesentlich mit charakterisieren und die Diagnosestellung erleichtern oder überhaupt erst ermöglichen. In anderen Fällen ist die Verknüpfung schwer zu belegen und läuft somit Gefahr, übersehen zu werden – insbesondere, wenn neurologische Symptome den intestinalen vorausgehen oder umgekehrt bzw. andere mögliche Ursachen bestehen. Neurologische Komplikationen sind sowohl bei den chronisch entzündlichen Darmerkrankungen im engeren Sinne als auch bei der Zöliakie und auch beim durch grampositive Bakterien verursachten Morbus Whipple beschrieben. Dieses Kapitel fasst die Literatur zu neurologischen Komplikationen der genannten entzündlichen Darmerkrankungen hinsichtlich ihrer Charakteristika, Diagnostik, Abgrenzung anderer Ursachen und therapeutischer Strategien zusammen.

Literatur

  1. Addolorato G, Di Giuda D, De Rossi G, Valenza V, Domenicali M, Caputo F et al (2004) Regional cerebral hypoperfusion in patients with celiac disease. Am J Med 116(5):312–317CrossRefPubMedGoogle Scholar
  2. Akbayir N, Calis AB, Alkim C, Sokmen HM, Erdem L, Ozbal A et al (2005) Sensorineural hearing loss in patients with inflammatory bowel disease: a subclinical extraintestinal manifestation. Dig Dis Sci 50(10):1938–1945CrossRefPubMedGoogle Scholar
  3. Anderson M (2000) Neurology of Whipple’s disease. J Neurol Neurosurg Psychiatry 68(1):2–5CrossRefPubMedPubMedCentralGoogle Scholar
  4. van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M et al (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn‘s disease. New Engl J Med 353(4):362–368CrossRefPubMedGoogle Scholar
  5. Bachmann O, Langer F, Rademacher J (2010) Pulmonary manifestations of inflammatory bowel disease. Der Internist 51(Suppl 1):264–268CrossRefPubMedGoogle Scholar
  6. Barbado FJ, Vazquez JJ, Gil A, Ortiz Vazquez J (1980) Vasculitis and ulcerative colitis. Gastroenterol 79(2):417–418Google Scholar
  7. Baron BW, Jeon HR, Glunz C, Peterson A, Cohen R, Hanauer S et al (2002) First two patients with ulcerative colitis who developed classical thrombotic thrombocytopenic purpura successfully treated with medical therapy and plasma exchange. J Clin Apheresis 17(4):204–206CrossRefPubMedGoogle Scholar
  8. Baumgart DC, Sandborn WJ (2007) Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369(9573):1641–1657CrossRefPubMedGoogle Scholar
  9. Berden JH, Hoitsma AJ, Merx JL, Keyser A (1985) Severe central-nervous-system toxicity associated with cyclosporin. Lancet 1(8422):219–220CrossRefPubMedGoogle Scholar
  10. Bernstein CN, Wajda A, Blanchard JF (2005) The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterol 129(3):827–836CrossRefGoogle Scholar
  11. Boulos A, Rolain JM, Raoult D (2004) Antibiotic susceptibility of Tropheryma whipplei in MRC5 cells. Antimicrob Agents Chemother 48(3):747–752CrossRefPubMedPubMedCentralGoogle Scholar
  12. Burk K, Bosch S, Muller CA, Melms A, Zuhlke C, Stern M et al (2001a) Sporadic cerebellar ataxia associated with gluten sensitivity. Brain: J Neurol 124(5):1013–1019CrossRefGoogle Scholar
  13. Burk K, Melms A, Schulz JB, Dichgans J (2001b) Effectiveness of intravenous immunoglobin therapy in cerebellar ataxia associated with gluten sensitivity. Ann Neurol 50(6):827–828CrossRefPubMedGoogle Scholar
  14. Carmona MA, Jaume Anselmi F, Ramirez Rivera J (2000) Cerebral thrombosis and vasculitis: an uncommon complication of ulcerative colitis. Bol Asoc Med P R 92(1–3):9–11PubMedGoogle Scholar
  15. Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD et al (2004) The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterol 126(1):19–31CrossRefGoogle Scholar
  16. Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A (2011) Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the therapeutics and technology assessment subcommittee of the American academy of Neurology. Neurol 76(3):294–300CrossRefGoogle Scholar
  17. Dimitrova AK, Ungaro RC, Lebwohl B, Lewis SK, Tennyson CA, Green MW et al (2013) Prevalence of migraine in patients with celiac disease and inflammatory bowel disease. Headache 53(2):344–355CrossRefPubMedGoogle Scholar
  18. Druschky A, Heckmann J, Engelhardt A, Neundorfer (1996) Myositis – a rare complication of Crohn disease. Fortschr Neurol Psychiatr 64(10):422–424CrossRefPubMedGoogle Scholar
  19. Duffy LF, Daum F, Fisher SE, Selman J, Vishnubhakat SM, Aiges HW et al (1985) Peripheral neuropathy in Crohn’s disease patients treated with metronidazole. Gastroenterol 88(3):681–684CrossRefGoogle Scholar
  20. Elsehety A, Bertorini TE (1997) Neurologic and neuropsychiatric complications of Crohn‘s disease. S Med J 90(6):606–610CrossRefGoogle Scholar
  21. Felber J, Aust D, Baas S, Bischoff S, Blaker H, Daum S et al (2014) Results of a S2k-Consensus Conference of the German Society of Gastroenterolgy, Digestive- and Metabolic Diseases (DGVS) in conjunction with the German Coeliac Society (DZG) regarding coeliac disease, wheat allergy and wheat sensitivity. Z Gastroenterol 52(7):711–743CrossRefPubMedGoogle Scholar
  22. Ferrante M, de Hertogh G, Hlavaty T, D‘Haens G, Penninckx F, D‘Hoore A et al (2006) The value of myenteric plexitis to predict early postoperative Crohn’s disease recurrence. Gastroenterol 130(6):1595–1606CrossRefGoogle Scholar
  23. Ferro JM, Oliveira S (2014) Neurologic manifestations of gastrointestinal and liver diseases. Curr Neurol Neurosci Rep 14(10):487CrossRefPubMedGoogle Scholar
  24. Feurle GE, Moos V, Schneider T, Fenollar F, Raoult D (2012) The combination of chloroquine and minocycline, a therapeutic option in cerebrospinal infection of Whipple‘s disease refractory to treatment with ceftriaxone, meropenem and co-trimoxazole. J Antimicrob Chemother 67(5):1295–1296CrossRefPubMedGoogle Scholar
  25. Figueroa JJ, Loftus EV Jr, Harmsen WS, Dyck PJ, Klein CJ (2013) Peripheral neuropathy incidence in inflammatory bowel disease: a population-based study. Neurol 80(18):1693–1697CrossRefGoogle Scholar
  26. Final report on the safety assessment of Ricinus (2007) Communis (Castor) Seed Oil, Hydrogenated Castor Oil, Glyceryl Ricinoleate, Glyceryl Ricinoleate SE, Ricinoleic Acid, Potassium Ricinoleate, Sodium Ricinoleate, Zinc Ricinoleate, Cetyl Ricinoleate, Ethyl Ricinoleate, Glycol Ricinoleate, Isopropyl Ricinoleate, Methyl Ricinoleate, and Octyldodecyl Ricinoleate. Int J Toxicol 26(Suppl 3):31–77Google Scholar
  27. Finnie IA, Shields R, Sutton R, Donnelly R, Morris AI (1994) Crohn‘s disease and myasthenia gravis: a possible role for thymectomy. Gut 35(2):278–279CrossRefPubMedPubMedCentralGoogle Scholar
  28. Freeman HJ (2008) Neurological disorders in adult celiac disease. Can J Gastroenterol = J Can gastroenterol 22(11):909–911CrossRefGoogle Scholar
  29. Galldiks N, Burghaus L, Vollmar S, Cizek J, Impekoven P, Thomas A et al (2004) Novel neuroimaging findings in a patient with cerebral Whipple‘s disease: a magnetic resonance imaging and positron emission tomography study. J Neuroimaging 4(4):372–376CrossRefGoogle Scholar
  30. Gelfenbeyn M, Goodkin R, Kliot M (2006) Sterile recurrent spinal epidural abscess in a patient with Crohn’s disease: a case report. Surg Neurol 65(2):178–184CrossRefPubMedGoogle Scholar
  31. Gerard A, Sarrot-Reynauld F, Liozon E, Cathebras P, Besson G, Robin C et al (2002) Neurologic presentation of Whipple disease: report of 12 cases and review of the literature. Med 81(6):443–457CrossRefGoogle Scholar
  32. Gobbele R, Reith W, Block F (2000) Cerebral vasculitis as a concomitant neurological illness in Crohn’s disease. Der Nervenarzt 71(4):299–304CrossRefPubMedGoogle Scholar
  33. Gobbi G, Bouquet F, Greco L, Lambertini A, Tassinari CA, Ventura A et al (1992) Coeliac disease, epilepsy, and cerebral calcifications. The Italian Working Group on Coeliac Disease and Epilepsy. Lancet 340(8817):439–443CrossRefPubMedGoogle Scholar
  34. Gondim FA, Brannagan TH 3rd, Sander HW, Chin RL, Latov N (2005) Peripheral neuropathy in patients with inflammatory bowel disease. Brain: J Neurol 128(4):867–879CrossRefGoogle Scholar
  35. Gower-Rousseau C, Reumaux D, Bellard M, Delecourt L, Ribet M, Colombel JF (1993) Remission of myasthenia gravis after proctocolectomy in a patient with ulcerative colitis. Am J Gastroenterol 88(7):1136–1138PubMedGoogle Scholar
  36. Gupta G, Gelfand JM, Lewis JD (2005) Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterol 129(3):819–826CrossRefGoogle Scholar
  37. Hadjivassiliou M, Aeschlimann P, Sanders DS, Maki M, Kaukinen K, Grunewald RA et al (2013) Transglutaminase 6 antibodies in the diagnosis of gluten ataxia. Neurol 80(19):1740–1745CrossRefGoogle Scholar
  38. Hadjivassiliou M, Boscolo S, Davies-Jones GA, Grunewald RA, Not T, Sanders DS et al (2002) The humoral response in the pathogenesis of gluten ataxia. Neurol 58(8):1221–1226CrossRefGoogle Scholar
  39. Hadjivassiliou M, Davies-Jones GA, Sanders DS, Grunewald RA (2003) Dietary treatment of gluten ataxia. J Neurol Neurosurg Psychiatry 74(9):1221–1224CrossRefPubMedPubMedCentralGoogle Scholar
  40. Hadjivassiliou M, Duker AP, Sanders DS (2014) Gluten-related neurologic dysfunction. Handb Clin Neurol 120:607–619CrossRefPubMedGoogle Scholar
  41. Hadjivassiliou M, Sanders DD, Aeschlimann DP (2015) Gluten-related disorders: gluten ataxia. Dig Dis 33(2):264–268CrossRefPubMedGoogle Scholar
  42. Hadjivassiliou M, Sanders DS, Grunewald RA, Woodroofe N, Boscolo S, Aeschlimann D (2010) Gluten sensitivity: from gut to brain. Lancet Neurol 9(3):318–330CrossRefPubMedGoogle Scholar
  43. Hadjivassiliou M, Sanders DS, Woodroofe N, Williamson C, Grunewald RA (2008) Gluten ataxia. Cerebellum 7(3):494–498CrossRefPubMedGoogle Scholar
  44. Hagel S, Epple HJ, Feurle GE, Kern WV, Lynen Jansen P, Malfertheiner P et al (2015) S2k-guideline gastrointestinal infectious diseases and Whipple’s disease. Z Gastroenterol 53(5):418–459CrossRefPubMedGoogle Scholar
  45. von Herbay A, Ditton HJ, Schuhmacher F, Maiwald M (1997) Whipple‘s disease: staging and monitoring by cytology and polymerase chain reaction analysis of cerebrospinal fluid. Gastroenterol 113(2):434–441CrossRefGoogle Scholar
  46. Heuer DK, Gager WE, Reeser FH (1982) Ischemic optic neuropathy associated with Crohn‘s disease. J Clin Neuroophthalmol 2(3):175–181PubMedGoogle Scholar
  47. Humbert P, Monnier G, Billerey C, Birgen C, Dupond JL (1989) Polyneuropathy: an unusual extraintestinal manifestation of Crohn’s disease. Acta Neurol Scand 80(4):301–306CrossRefPubMedGoogle Scholar
  48. Hunt KA, Zhernakova A, Turner G, Heap GA, Franke L, Bruinenberg M et al (2008) Newly identified genetic risk variants for celiac disease related to the immune response. Nat Genet 40(4):395–402CrossRefPubMedPubMedCentralGoogle Scholar
  49. Johns DR (1991) Cerebrovascular complications of inflammatory bowel disease. Am J Gastroenterol 86(3):367–370PubMedGoogle Scholar
  50. Karajeh MA, Hadjivassiliou M, Hurlstone P, Grundman MJ (2004) Neurological sequelae of Crohn’s disease: opportunity to study common etiological pathways. J Gastroenterol Hepatol 19(9):1093–1094CrossRefPubMedGoogle Scholar
  51. Lagier JC, Fenollar F, Lepidi H, Giorgi R, Million M, Raoult D (2014) Treatment of classic Whipple‘s disease: from in vitro results to clinical outcome. J Antimicrob Chemother 69(1):219–227CrossRefPubMedGoogle Scholar
  52. Lagier JC, Fenollar F, Lepidi H, Raoult D (2010) Failure and relapse after treatment with trimethoprim/sulfamethoxazole in classic Whipple‘s disease. J Antimicrob Chemother 65(9):2005–2012CrossRefPubMedGoogle Scholar
  53. Lam MC, Bressler B (2014) Vedolizumab for ulcerative colitis and Crohn‘s disease: results and implications of GEMINI studies. Immunother 6(9):963–971CrossRefGoogle Scholar
  54. Le Blay P, Rakotonirainy H, Lagier JC, Raoult D, Puechal X, Pers YM (2014) A severe Whipple disease with an immune reconstitution inflammatory syndrome: an additional case of thalidomide efficiency. Jt Bone spine: Rev Rhum 81(3):260–262CrossRefGoogle Scholar
  55. Levenstein S, Prantera C, Varvo V, Scribano ML, Andreoli A, Luzi C et al (2000) Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission. Am J Gastroenterol 95(5):1213–1220CrossRefPubMedGoogle Scholar
  56. Lossos A, River Y, Eliakim A, Steiner I (1995) Neurologic aspects of inflammatory bowel disease. Neurol 45(3 Pt 1):416–421CrossRefGoogle Scholar
  57. Louis ED (2003) Whipple disease. Curr Neurol Neurosci Rep 3(6):470–475CrossRefPubMedGoogle Scholar
  58. Louis ED, Lynch T, Kaufmann P, Fahn S, Odel J (1996) Diagnostic guidelines in central nervous system Whipple‘s disease. Ann Neurol 40(4):561–568CrossRefPubMedGoogle Scholar
  59. Luostarinen L, Himanen SL, Luostarinen M, Collin P, Pirttila T (2003) Neuromuscular and sensory disturbances in patients with well treated coeliac disease. J Neurol Neurosurg Psychiatry 74(4):490–494CrossRefPubMedPubMedCentralGoogle Scholar
  60. Mahnel R, Marth T (2004) Progress, problems, and perspectives in diagnosis and treatment of Whipple’s disease. Clin Exp Med 4(1):39–43CrossRefPubMedGoogle Scholar
  61. Manzel K, Tranel D, Cooper G (2000) Cognitive and behavioral abnormalities in a case of central nervous system Whipple disease. Arch Neurol 57(3):399–403CrossRefPubMedGoogle Scholar
  62. Masuda H, Ishii U, Aoki N, Nakayama H, Sato F, Karube H et al (2002) Ulcerative colitis associated with Takayasu’s disease in two patients who received proctocolectomy. J Gastroenterol 37(4):297–302CrossRefPubMedGoogle Scholar
  63. Menard DB, Haddad H, Blain JG, Beaudry R, Devroede G, Masse S (1976) Granulomatous myositis and myopathy associated with crohn’s colitis. N Engl J Med 295(15):818–819CrossRefPubMedGoogle Scholar
  64. Miehsler W, Reinisch W, Valic E, Osterode W, Tillinger W, Feichtenschlager T et al (2004) Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 53(4):542–548CrossRefPubMedPubMedCentralGoogle Scholar
  65. Moos V, Feurle GE, Schinnerling K, Geelhaar A, Friebel J, Allers K et al (2013) Immunopathology of immune reconstitution inflammatory syndrome in Whipple’s disease. J Immunol 190(5):2354–2361CrossRefPubMedGoogle Scholar
  66. Murai H, Tokunaga H, Kubo I, Kawajiri M, Iwaki T, Taniwaki T et al (2006) Myeloradiculitis caused by Cryptococcus neoformans infection in a patient with ulcerative colitis: a neuropathological study. J Neurol Sci 247(2):236–238CrossRefPubMedGoogle Scholar
  67. Nelson J, Barron MM, Riggs JE, Gutmann L, Schochet SS Jr (1986) Cerebral vasculitis and ulcerative colitis. Neurol 36(5):719–721CrossRefGoogle Scholar
  68. Oldenburg B, Van Tuyl BA, van der Griend R, Fijnheer R, van Berge Henegouwen GP (2005) Risk factors for thromboembolic complications in inflammatory bowel disease: the role of hyperhomocysteinaemia. Dig Dis Sci 50(2):235–240CrossRefPubMedGoogle Scholar
  69. Panani AD, Grigoriadou M, Magira E, Roussos C, Raptis SA (2006) Perinuclear antineutrophil cytoplasmic antibody myeloperoxidase-positive vasculitis in association with ulcerative colitis. Clin Rheumatol 25(1):35–37CrossRefPubMedGoogle Scholar
  70. Purrmann J, Arendt G, Cleveland S, Borchard F, Furst W, Gemsa R et al (1992) Association of Crohn’s disease and multiple sclerosis. Is there a common background? J Clin Gastroenterol 14(1):43–46CrossRefPubMedGoogle Scholar
  71. Qureshi JA, Staugaitis SM, Calabrese LH (2002) Neutrophilic myositis: an extra-intestinal manifestation of ulcerative colitis. J Clin Rheumatol 8(2):85–88CrossRefPubMedGoogle Scholar
  72. Rashtak S, Ettore MW, Homburger HA, Murray JA (2008) Comparative usefulness of deamidated gliadin antibodies in the diagnosis of celiac disease. Clin Gastroenterol Hepatol 6(4):426–432; quiz 370CrossRefPubMedPubMedCentralGoogle Scholar
  73. Reinshagen M, Folsch UR (2004) Extraintestinal manifestations in ulcerative colitis. Z Gastroenterol 42(9):1024–1028PubMedGoogle Scholar
  74. Richard S, Fairise A, Lacour JC, Ducrocq X (2010) Cerebral venous thrombosis in inflammatory bowel diseases. Inflamm Bowel Dis 16(3):366–367CrossRefPubMedGoogle Scholar
  75. Romero Aroca P, Salvat Serra M, Perena Soriano F, Martinez Salcedo I (2001) Anterior optic neuritis do to ulcerative colitis. Arch Soc Esp Oftalmologia 76(3):189–191Google Scholar
  76. Scheid R, Teich N (2007) Neurologic manifestations of ulcerative colitis. Eur J Neurol 14(5):483–493CrossRefPubMedGoogle Scholar
  77. van de Scheur MR, van der Waal RI, van Bodegraven AA, Volker-Dieben HJ, Starink TM, van der Waal I (2002) Cheilitis granulomatosa and optic neuropathy as rare extraintestinal manifestations of Crohn’s disease. J Clin Gastroenterol 34(5):557–559CrossRefPubMedGoogle Scholar
  78. Schnider PJ, Reisinger EC, Gerschlager W, Muller C, Berger T, Krejs GJ et al (1996) Long-term follow-up in cerebral Whipple’s disease. Eur J Gastroenterol Hepatol 8(9):899–903PubMedGoogle Scholar
  79. Shen TC, Lebwohl B, Verma H, Kumta N, Tennyson C, Lewis S et al (2012) Peripheral neuropathic symptoms in celiac disease and inflammatory bowel disease. J Clin Neuromuscul Dis 13(3):137–145CrossRefPubMedGoogle Scholar
  80. Tarabar D, Hirsch A, Rubin DT (2016) Vedolizumab in the treatment of Crohn’s disease. Expert Rev Gastroenterol Hepatol 10(3):283–290CrossRefPubMedGoogle Scholar
  81. Thomas CW Jr, Weinshenker BG, Sandborn WJ (2004) Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn’s disease. Inflamm Bowel Dis 10(1):28–31CrossRefPubMedGoogle Scholar
  82. Watkinson G (1986) Sulphasalazine: a review of 40 years’ experience. Drugs 32(Suppl 1):1–11CrossRefPubMedGoogle Scholar
  83. Weber P, Husemann S, Vielhaber H, Zimmer KP, Nowak-Gottl U (1999) Coagulation and fibrinolysis in children, adolescents, and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 28(4):418–422CrossRefPubMedGoogle Scholar
  84. West J, Logan RF, Hill PG, Lloyd A, Lewis S, Hubbard R et al (2003) Seroprevalence, correlates, and characteristics of undetected coeliac disease in England. Gut 52(7):960–965CrossRefPubMedPubMedCentralGoogle Scholar
  85. Whipple G (1907) A hitherto undescribed disease characterized anatomically by deposits of fat and fatty acid in the intestinal and mesenteric lymphatic tissues. Bull Johns Hopkins Hosp 18:382–393Google Scholar
  86. WJ SRaS (Hrsg) (2004) Inflammatory bowel diseases: saundersGoogle Scholar
  87. Yesilova Z, Naharci I, Uygun A, Ulas HU, Dagalp K (2006) Motor axonal polyneuropathy in the course of ulcerative colitis: a case report. Turk J Gastroenterol 17(1):58–61PubMedGoogle Scholar
  88. Zois CD, Katsanos KH, Kosmidou M, Tsianos EV (2010) Neurologic manifestations in inflammatory bowel diseases: current knowledge and novel insights. J Crohn’s Colitis 4(2):115–124CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Medizinische Hochschule HannoverKlinik für Gastroenterologie, Hepatologie und EndokrinologieHannoverDeutschland
  2. 2.Asklepios Klinik AltonaGastroenterologie – GastroClinicHamburgDeutschland

Personalised recommendations